Show simple item record

dc.contributor.authorShablak, Alaaeldin
dc.contributor.authorHawkins, Robert E
dc.contributor.authorRothwell, Dominic G
dc.contributor.authorElkord, Eyad
dc.date.accessioned2010-08-09T15:13:39Z
dc.date.available2010-08-09T15:13:39Z
dc.date.issued2009-11-01
dc.identifier.citationT cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. 2009, 15 (21):6503-10 Clin. Cancer Res.en
dc.identifier.issn1078-0432
dc.identifier.pmid19843660
dc.identifier.doi10.1158/1078-0432.CCR-09-1605
dc.identifier.urihttp://hdl.handle.net/10541/109332
dc.description.abstractMetastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.
dc.language.isoenen
dc.subjectCancer Antigensen
dc.subjectKidney Canceren
dc.subjectTumour-Infiltrating Lymphocytesen
dc.subjectCancer Metastasisen
dc.subject.meshAdoptive Transfer
dc.subject.meshAntigens, Neoplasm
dc.subject.meshAutoimmunity
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshImmunotherapy
dc.subject.meshKidney Neoplasms
dc.subject.meshKiller Cells, Lymphokine-Activated
dc.subject.meshKiller Cells, Natural
dc.subject.meshLymphocytes, Tumor-Infiltrating
dc.subject.meshNeoplasm Metastasis
dc.subject.meshT-Lymphocytes
dc.titleT cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, School of Cancer, Enabling Sciences and Technology, The University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, United Kingdom.en
dc.identifier.journalClinical Cancer Researchen
html.description.abstractMetastatic renal cell carcinoma (MRCC) remains a challenging malignancy to treat. Cancer immunotherapies have been extensively explored in melanoma and RCC as they poorly respond to conventional cytotoxic agents but show responses to a variety of immunologic agents. The recent considerable success of T cell-based immunotherapy in melanoma warrants further efforts to apply this treatment to other cancers including MRCC. Although RCC is an immunosensitive cancer, similar attempts in MRCC have shown a very limited success. In this review, we summarize the clinical data on T cell-based immunotherapies for MRCC showing the modest success that has been achieved to date. More importantly, we discuss potential strategies for improving its efficacy for the treatment of MRCC in light of the important achievements for treating metastatic melanoma. In particular, the growing evidence of success by combining expanded tumor-infiltrating lymphocytes with lymphodepletion merits investigation in MRCC. Identifying new RCC-associated antigens, optimized methods, and conditions for detection, isolation, and/or modification and expansion of tumor-specific T cells are all important strategies to be pursued for improving T cell-based immunotherapy of MRCC.


This item appears in the following Collection(s)

Show simple item record